Dual role of eugenol on chronic gastric ulcer in rats: Low-dose healing efficacy and the worsening gastric lesion in high doses

Longo, Bruna; Sommerfeld, Ellen Perfoll; Santos, Ana Caroline dos; Silva, Rita de Cássia Melo Vilhena de Andrade Fonseca da; Somensi, Líncon Bordignon; Mariano, Luísa Nathália Bolda; Boeing, Thaise; Andrade, Sérgio Faloni de; Souza, Priscila de; Silva, Luísa Mota da

doi:10.1016/j.cbi.2020.109335

Cited by 14 publications

(9 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…2). Previous studies in a model of gastric lesion induced by indomethacin show an increase in PGE 2 levels after treatment of ulcerated animals with LS (Somensi et al, 2021) an effect that may be responsible for the increase in mucin levels also observed in the present study. So, the increase in mucin levels induced by LS treatment may be related to a key healing factor, since it plays an important role as a barrier against gastric injury caused by luminal acid, bacteria, and physical damage to the epithelium (Chen et al, 2005).…”

Section: Discussionsupporting

confidence: 86%

“…Furthermore, studies with oleanolic acid and a pentacyclic triterpene, which are structurally related to LS, have shown gastric healing action in both in vitro and in vivo studies, like those found in the present study (Rodríguez, et al, 2003;Sánchez et al, 2006). The in vivo antioxidant value of LS was already evidenced using acute ulcer models (Somensi et al, 2021) [17] and research with antioxidants shows that they can interfere with the in ammatory process induced by acetic acid, reducing gastric damage by decreasing the volume and total acidity of gastric secretion and cell proliferation (Silva et al, 2013;Almasaudi et al, 2017;Prazereset al, 2019;Longo et al, 2021).…”

Section: Discussionsupporting

confidence: 81%

“…Starting experimental investigations on the antiulcer potential of Lupeol stearate (LS), our research group showed that this compound promotes an important gastroprotective effect against gastric lesions induced by ethanol in rodents (Somensi et al, 2021). Given those results, the present study evaluated the capacity of LS to accelerates the gastric healing process in chronic and recurrent gastric ulcer model.…”

Section: Discussionmentioning

confidence: 97%

“…Lupeol was isolated from Maytenus salicifolia Reissek (Celastraceae) hexanic extract as described in details by Magalhães et al (2011) and esteri cation with appropriate reagents gave rise to LS was performed as described in details by Silva et al (2017). The oral gastroprotective dose of LS of 1 mg/kg was chosen to be employed in this study based in ndings from Somensi et al (2021).…”

Section: Obtaining Lupeol Stearate (Ls) and Choice Of Dosementioning

confidence: 99%

“…Indeed, this triterpene has several biological activities, including anticancer properties (Abu-La et al, 2019;Shen et al, 2019), anti-diabetic effects (Giacoman-Martínez et al, 2019), anti-in ammatory actions (Milani et al, 2019), antimalarial potency (Singh et al, 2019) and is a candidate as a non-hormonal male contraceptive (Arifuzzuman et al, 2018). Recently, through the esteri cation of Lupeol, it was possible to obtain Lupeol stearate (LS), a derivative with potent gastroprotective activity (Somensi et al, 2021). Indeed, the con rmation of the potent gastroprotection provided by LS in acute gastric ulcer models through a preventive and non-therapeutic approach by our research group has shed light on new questions regarding the anti-ulcer potential of this ester.…”

Section: Introductionmentioning

confidence: 99%

See 4 more Smart Citations

Lupeol Stearate Accelerates Healing and Prevents Recurrence of Gastric Ulcer in Rodents

Somensi¹,

Costa²,

Boeing³

et al. 2021

Preprint

Self Cite

View full text Add to dashboard Cite

The gastric healing and gastric ulcer recurrence preventive effect of Lupeol Stearate (LS) was measured in this study. To evaluate the gastric healing effect, rats were submitted to the 80% acetic acid-induced ulcer model and treated with vehicle (1 ml/kg, p.o.), LS (1 mg/kg, p.o.) or omeprazole (20 mg/kg, p.o.) twice a day for seven days. The gastric injury was evaluated macroscopically, histologically and histochemical; and biochemical parameters were also quantified. To evaluate the effects of LS on gastric ulcer recurrence, mice were ulcerated by gastric instillation of 10% acetic acid and treated with vehicle (1 ml/kg, p.o.), LS (1 mg/kg, p.o.) or ranitidine (20 mg/kg, p.o.) twice a day for ten days. Then, the ulcer recurrence in these animals was induced by IL- 1β (1 µg/kg i.p) at five day after the end of the treatment period. The area of the lesion recurred were measured, as well as the activity of myeloperoxidase and TNF levels. Oral treatment with LS accelerated gastric healing by 63% compared to the group treated with vehicle, which was also evidenced by histological improvement and increased production of mucin in the gastric epithelium. LS elevated the activity of the glutathione S-transferase and reduced the activity of myeloperoxidase, but did not change the levels of reduced glutathione or the activity of superoxide dismutase and catalase at the ulcer site in rats. Regarding the recurrence, the LS treatment reduced the recurred lesions, reducing MPO activity but not TNF levels at ulcer site. It can be concluded that LS promotes the healing of gastric lesions by favoring the mucus production and reducing the migration of neutrophils and that it can reduce the severity of the ulcer recurrence.

show abstract

Section: Discussionsupporting

confidence: 86%